文献速递免疫规划卫生政策与健康促进

澳大利亚国家疫苗接种项目实施前后带状疱疹疫苗覆盖率

Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program.
PubMed 文献 · Vaccine · 2020-03-31

本研究利用全国电子初级保健数据集MedicineInsight,分析2016-2018年间70-79岁常规就诊者的带状疱疹疫苗接种情况。2016、2017、2018年各年常规就诊者平均月度接种率分别为5.5%、3.3%、1.6%;截至2018年12月31日累计疫苗覆盖率为46.9%(25,791/55,034),采用替代常规就诊者定义时为41.6%(27,040/65,010)。覆盖率因性别、辖区、偏远程度和社会经济劣势而异。作者认为覆盖率仍不理想,电子病历可补充其他数据用于估计疫苗覆盖率。

要点

  • 2016、2017、2018年70-79岁常规就诊者平均月度接种率分别为5.5%、3.3%、1.6%。
  • 截至2018年12月31日累计疫苗覆盖率为46.9%(25,791/55,034),替代定义下为41.6%(27,040/65,010)。
  • 女性覆盖率48.5%高于男性45.1%(调整OR=1.1,95%CI:1.1-1.2)。

核心结论

  • 本研究的带状疱疹疫苗覆盖率估计值显著高于唯一其他基于澳大利亚免疫登记处的报告,但仍提示接种率不理想。
  • 使用电子病历可补充其他数据用于估计澳大利亚成人疫苗覆盖率。

研究设计与样本

  • 使用全国去标识化电子初级保健数据集MedicineInsight,提取2016-2018年间年龄50-90岁患者记录。
  • 在常规就诊者(前两年每年至少就诊一次)中,估计目标人群(70-79岁)自项目实施以来各年的粗率和调整平均月度带状疱疹疫苗接种率,以及截至2018年12月的累计疫苗覆盖率。
  • 采用多变量逻辑回归分析与较高覆盖率相关的特征。

主要发现

  • 2016、2017、2018年转为70-79岁的常规就诊者分别为52,229、55,034、57,316人,平均月度疫苗接种率分别为5.5%、3.3%、1.6%。
  • 截至2018年12月31日,常规就诊成人估计累计疫苗覆盖率为46.9%(25,791/55,034);采用替代常规就诊者定义时为41.6%(27,040/65,010)。
  • 疫苗覆盖率因性别而异:女性48.5% vs 男性45.1%(调整OR=1.1,95%CI:1.1-1.2)。
  • 疫苗覆盖率因辖区而异:与New South Wales的43.7%相比,South Australia为55.6%(aOR=1.6,95%CI:1.5-1.8),Northern Territory为27.6%(aOR=0.6,95%CI:0.5-0.7)。
  • 疫苗覆盖率因偏远程度和社会经济劣势而异:与主要城市的47.6%相比,偏远/极偏远地区为38.2%(aOR=0.7,95%CI:0.6-0.8);与最劣势地区的41.8%相比,最优势地区为48.6%(aOR=1.6,95%CI:1.2-2.1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Australia, a herpes zoster (HZ) vaccination program targeting adults aged 70 years old with catch-up for those 71-79 years began in November 2016 but there is limited information on vaccine uptake and coverage achieved since commencement. METHODS: We used a national de-identified electronic primary care dataset, MedicineInsight, and extracted records from patients turning 50-90 years old during 2016-2018. Among patients considered regular attenders, with at least one visit per year in the two years prior, we estimated the crude and adjusted average monthly HZ vaccine uptake in the target population (70-79 years old) for each year since program implementation as well as cumulative vaccine coverage until December 2018. Multivariate logistic regression was used to analyse characteristics associated with higher coverage. RESULTS: Among 52,229, 55,034, and 57,316 regular attenders turning 70-79 years old in 2016, 2017 and 2018 respectively, the average monthly vaccine uptake rate was 5.5%, 3.3%, and 1.6% respectively. Up to 31st December 2018, the estimated cumulative vaccine coverage in regularly attending adults was 46.9% (25,791/55,034). It was substantially lower at 41.6% (27,040/65,010) using an alternate definition of a regular attender. Vaccine coverage differed by sex (women: 48.5% versus men: 45.1%, adjusted OR = 1.1, 95% CI: 1.1-1.2); by jurisdiction (compared to New South Wales: 43.7%, South Australia: 55.6%, aOR = 1.6, 95% CI (1.5-1.8); Northern Territory: 27.6%, aOR = 0.6, (0.5-0.7)); by remoteness status (compared to major cities: 47.6%, remote/very remote areas: 38.2%, aOR = 0.7, (0.6-0.8)); and by socioeconomic disadvantage (compared to most disadvantaged: 41.8%, most advantaged: 48.6%, aOR = 1.6 (1.2-2.1)). CONCLUSIONS: Our estimates of HZ vaccine coverage are substantially higher than the only other reports based on the Australian Immunisation Register however they still suggest that uptake is suboptimal. The use of electronic medical records can complement other data for estimating vaccine coverage in Australian adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lin J, Wood JG, Bernardo C, et al. Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program. Vaccine. 2020. PMID: 32245643. doi:10.1016/j.vaccine.2020.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。